Novartis' Mayzent EU approval offers SPMS patients new optio...

Novartis’ Mayzent has been approved in Europe for adults with secondary progressive multiple sclerosis (SPMS) and active disease.

Novartis strikes landmark deal with NHS to speed up inclisir...

Ligelizumab could top Xolair in chronic hives, says Novartis

Novartis sets up free lottery for $2.1m SMA drug outside US

Novartis is planning to give away 100 doses of its hugely expensive spinal muscular atrophy gene therapy Zolgensma in countries outside the US where it is not yet approved, in a controversi

2019: the year of the pharma mega-merger

2019 will be remembered as the year of the pharma mega-merger. Richard Staines looks back at a year that changed the landscape of big pharma

Novartis top of pile in European pharma in 2020, say Jefferi...

Jefferies’ team of analysts have recently been touting Roche as their favourite big European pharma – but going into 2020 it’s Novartis that gets the strongest “buy” rating in a broker note